114 related articles for article (PubMed ID: 22166275)
61. Concordant anencephaly in monoamniotic twins and an analysis of maternal serum markers.
Hansen LM; Donnenfeld AE
Prenat Diagn; 1997 May; 17(5):471-3. PubMed ID: 9178324
[TBL] [Abstract][Full Text] [Related]
62. Elevated second-trimester maternal serum hCG alone or in combination with elevated alpha-fetoprotein.
Benn PA; Horne D; Briganti S; Rodis JF; Clive JM
Obstet Gynecol; 1996 Feb; 87(2):217-22. PubMed ID: 8559527
[TBL] [Abstract][Full Text] [Related]
63. [Localization of gestational age reference table and its application in prenatal screening].
Dou L; Yang G; Mo W
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2017 Jan; 46(1):59-65. PubMed ID: 28436632
[TBL] [Abstract][Full Text] [Related]
64. Maternal serum screening: practice patterns of physicians in Newfoundland.
Chandra S; Crane J; Hutchens D; Bennett K; O'Grady T; Duff A; Macgregor D
J Obstet Gynaecol Can; 2003 Oct; 25(10):825-9. PubMed ID: 14532950
[TBL] [Abstract][Full Text] [Related]
65. Relation between maternal weight and serum alpha-fetoprotein concentration during the second trimester.
Haddow JE; Kloza EM; Knight GJ; Smith DE
Clin Chem; 1981 Jan; 27(1):133-4. PubMed ID: 6160923
[TBL] [Abstract][Full Text] [Related]
66. Differences in practice patterns between obstetricians and family physicians: use of serum screening.
Yankowitz J; Howser DM; Ely JW
Am J Obstet Gynecol; 1996 Apr; 174(4):1361-5. PubMed ID: 8623870
[TBL] [Abstract][Full Text] [Related]
67. Critical issues in prenatal maternal serum alpha-fetoprotein screening for genetic anomalies.
Macri JN
Am J Obstet Gynecol; 1986 Aug; 155(2):240-6. PubMed ID: 2426946
[TBL] [Abstract][Full Text] [Related]
68. Maternal serum alpha-fetoprotein screening: the effect of participation on anxiety and attitude toward pregnancy in women with normal results.
Burton BK; Dillard RG; Clark EN
Am J Obstet Gynecol; 1985 Jul; 152(5):540-3. PubMed ID: 2409796
[TBL] [Abstract][Full Text] [Related]
69. Awareness and use of maternal serum screening among women from the St. John's region of Newfoundland and Labrador.
Cavanagh J; Mathews M; Crane J
J Obstet Gynaecol Can; 2007 Aug; 29(8):630-4. PubMed ID: 17714615
[TBL] [Abstract][Full Text] [Related]
70. Alpha-fetoprotein concentrations in maternal serum: relation to race and body weight.
Crandall BF; Lebherz TB; Schroth PC; Matsumoto M
Clin Chem; 1983 Mar; 29(3):531-3. PubMed ID: 6186415
[TBL] [Abstract][Full Text] [Related]
71. Regional variations in neural tube defects and alfa-fetoprotein screening in Denmark 1983-88.
Jacobsen P
Acta Obstet Gynecol Scand; 1996 Aug; 75(7):620-3. PubMed ID: 8822653
[TBL] [Abstract][Full Text] [Related]
72. Effects of feto-placental markers with plasma exchange in pregnancy.
Gerhardt RE; Koethe JD; Ntoso KA; Lodge S; Schlaff S; Wolf CJ
J Clin Apher; 1994; 9(1):6-9. PubMed ID: 7515046
[TBL] [Abstract][Full Text] [Related]
73. Hepatic mesenchymal hamartoma associated with mesenchymal stem villous hyperplasia of the placenta.
Kitano Y; Ruchelli E; Weiner S; Adzick NS
Fetal Diagn Ther; 2000; 15(3):134-8. PubMed ID: 10781996
[TBL] [Abstract][Full Text] [Related]
74. Pregnancy in renal transplant patients: Renal function markers and maternal-fetal outcomes.
Tebet JLS; Kirsztajn GM; Facca TA; Nishida SK; Pereira AR; Moreira SR; Medina JOP; Sass N
Pregnancy Hypertens; 2019 Jan; 15():108-113. PubMed ID: 30825905
[TBL] [Abstract][Full Text] [Related]
75. Use of Maternal Race and Weight Provides Equitable Performance in Serum Screening for Open Neural Tube Defects.
Messerlian G; Strickland SW; Willbur J; Vaughan C; Koenig S; Wright T; Palomaki GE
Clin Chem; 2024 Jul; 70(7):948-956. PubMed ID: 38965696
[TBL] [Abstract][Full Text] [Related]
76. Maternal weight differences do not explain ethnic differences in biochemical screening.
Bryant-Greenwood PK; O'Brien JE; Huang X; Yaron Y; Ayoub M; Johnson MP; Evans MI
Fetal Diagn Ther; 1998; 13(1):46-8. PubMed ID: 9605617
[TBL] [Abstract][Full Text] [Related]
77. Maternal serum alphafetoprotein screening for open neural tube defects: revised statistical parameters.
Wald NJ; Hackshaw AK; Cuckle HS
BJOG; 2000 Feb; 107(2):296-8. PubMed ID: 10688521
[No Abstract] [Full Text] [Related]
78. Quad Screen Test, A Multiplexed Biomarker Assay for Prenatal Screening to Assess Birth Defects: The Columbia University Experience Using the Beckman Access2 Immunoassay Analyzer and Benetech PRA.
Tecleab A; Lyashchenko AK; Rai AJ
Methods Mol Biol; 2019; 1885():297-307. PubMed ID: 30506206
[TBL] [Abstract][Full Text] [Related]
79. Birth weight, breast cancer and the potential mediating hormonal environment.
Bukowski R; Chlebowski RT; Thune I; Furberg AS; Hankins GD; Malone FD; D'Alton ME
PLoS One; 2012; 7(7):e40199. PubMed ID: 22815728
[TBL] [Abstract][Full Text] [Related]
80. Why do women choose or decline maternal serum screening?
Park AD; Mathews M
J Obstet Gynaecol Can; 2009 Feb; 31(2):149-55. PubMed ID: 19327214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
